Tag Archives: CEOs

Fixing Innovation: Lilly's CEO Says Why, and How

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing | Also tagged , , , , , , , , , , , , | 1 Comment

Unmet Need in the Migraine Space?

Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.
Posted in FDA, Global, Marketing, Regulatory, Strategy, Technology | Also tagged , , , | 2 Comments

Medco CEO Champions Robots Over Pharmacists

The role of the pharmacist in positive health outcomes – and drug company profits – is often cited in discussions around adherence to medication regimens, holistic prescribing practices and the navigation of insurance payment structures. In an attempt to demystify that role, Medco CEO David Snow told attendees at the Cleveland Clinic’s Medical Innovation Summit last [...]
Posted in Regulatory, Strategy, patient education, pricing | Also tagged , , , | 22 Comments

The UK NHS is Many Things. Evil isn’t One of Them.

Far be it from me to politicize this blog, but I have great trouble understanding how anyone can brand a system based on the principles of providing healthcare for all as ‘evil’.  The UK NHS has many flaws. It is over-stretched, weary, beleaguered, underfunded, occasionally incompetent, occasionally misguided, in parts outmoded, over-managed and often frustrating. But [...]
Posted in Global, Regulatory | Also tagged , , , , | 1 Comment